1357947-08-0

Basic information

• Product Name: 4-c]pyridine
• Synonyms: 5-broMo-3-iodo-1H-pyrazolo[3,4-c]pyridine;1H-Pyrazolo[3,4-c]pyridine, 5-bromo-3-iodo-
• CAS NO: 1357947-08-0
• Molecular Formula: C6H3BrIN3
• Molecular Weight: 323.91659
• Mol File: 1357947-08-0.mol

Chemical Properties

• Boiling Point: 458.7±40.0 °C(Predicted)
• Appearance: /
• Density: 2.559±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.72±0.40(Predicted)
• CAS DataBase Reference: 4-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-c]pyridine(1357947-08-0)
• EPA Substance Registry System: 4-c]pyridine(1357947-08-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1357947-08-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-c]pyridine is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicine.
Used in Agrochemical Production:
In the agrochemical industry, 4-c]pyridine serves as a crucial component in the creation of pesticides and other agricultural chemicals. Its incorporation into these products helps improve their effectiveness in protecting crops and controlling pests.
Used in Polymer Production:
4-c]pyridine is also used in the production of polymers, which are essential in various industries, including plastics, textiles, and coatings. Its presence in these materials can enhance their properties, such as strength, durability, and resistance to environmental factors.
Used in Industrial Chemicals:
4-c]pyridine is employed in the synthesis of other industrial chemicals, where its reactivity and aromatic nature contribute to the development of new and improved chemical products for various applications.
Overall, 4-c]pyridine is a versatile and valuable compound in the fields of organic chemistry, pharmaceuticals, agrochemicals, polymers, and industrial chemicals, thanks to its unique structure and properties.

Upstream product

• 929617-35-6 5-bromo-1H-pyrazolo[3,4m-c]pyridine 
• 23056-47-5 2-bromo-4-methyl-5-nitropyridine 
• 156118-16-0 6-bromo-4-methyl-pyridin-3-ylamine 

Downstream Products

• 1369509-72-7 5-bromo-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine 

Relevant articles and documents

CD73 INHIBITORS

Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'-nucleotidase, ecto is also provided.

Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors

Pim kinase inhibitors are promising cancer therapeutics. Pim-2, among the three Pim isoforms, plays a critical role in multiple myeloma yet inhibition of Pim-2 is challenging due to its high affinity for ATP. A co-crystal structure of a screening hit 1 bound to Pim-1 kinase revealed the key binding interactions of its indazole core within the ATP binding site. Screening of analogous core fragments afforded 1H-pyrazolo[3,4-c]pyridine (6-azaindazole) as a core for the development of pan-Pim inhibitors. Fragment and structure based drug design led to identification of the series with picomolar biochemical potency against all three Pim isoforms. Desirable cellular potency was also achieved.

PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.